Clinicopathological Significance of Tumor Stem Cell Markers ALDH1 and CD133 in Colorectal Carcinoma

Overview

Journal Iran J Pathol

Date 2021 Jan 4

PMID 33391379

Citations 6

Authors

Maryam Rezaee

Elmira Gheytanchi

Zahra Madjd

Mitra Mehrazma

Affiliations

Soon will be listed here.

Abstract

Background & Objective: Colorectal cancer (CRC) is the third most common cancer worldwide with a high mortality rate. The main causes of death in patients are recurrence and metastasis which are mainly attributed to the small subpopulation of cells within tumors called cancer stem cells (CSCs). This study aimed to evaluate the correlation between the expression of ALDH1 and CD133 as CSC associated markers and clinicopathological characteristics in CRC.

Methods: In this cross-sectional study, a total of 483 CRC tumor samples were immunohistochemically stained for detection of CD133 and ALDH1 markers. Correlations of marker expression with clinicopathological factors were also evaluated.

Results: There was a significant correlation between the luminal intensity of CD133 and neural invasion (=0.05) and between the cytoplasmic intensity of CD133 and metastasis (=0.05). In terms of H-score, a positive significant relation was observed between cytoplasmic expression of CD133 and lymph node (=0.02), neural (=0.04) and vascular invasion (=0.02). The ALDH1 cytoplasmic expression showed a significant correlation with tumor size (=0.001).

Conclusion: Our findings showed that increased expression of CD133 and ALDH1 is associated with tumor progression and worse outcomes in CRC patients. These markers can be good candidates for localized targeting of CSCs using antibodies. Future researches need to be improved approaches for early detection of CRC, and treatment monitoring for CRC and other cancers.

Citing Articles

Evaluation and Clinicopathological Correlation of ALDH1 in Colorectal Adenoma with Low-/High-Grade Dysplasia and Carcinoma.

Bhanu H, Mittal R, Senapati U South Asian J Cancer. 2025; 13(4):325-331.

PMID: 40060346 PMC: 11888799. DOI: 10.1055/s-0043-1774402.

Nanomaterial-based detection of circulating tumor cells and circulating cancer stem cells for cancer immunotherapy.

Yun Y, Kim S, Lee S, Cho H, Choi J Nano Converg. 2024; 11(1):56.

PMID: 39671082 PMC: 11645384. DOI: 10.1186/s40580-024-00466-x.

Early Onset Colorectal Cancer: Molecular Underpinnings Accelerating Occurrence.

Zinkeng A, Taylor F, Cheong S, Song H, Merchant J Cell Mol Gastroenterol Hepatol. 2024; 19(2):101425.

PMID: 39510499 PMC: 11731505. DOI: 10.1016/j.jcmgh.2024.101425.

Mechanisms underlying the changes in acetaldehyde dehydrogenase 1 in cholangiocarcinoma.

Ding B, Song Y, Liu S, Peng C, Zhang Y J Cancer. 2023; 14(17):3203-3213.

PMID: 37928420 PMC: 10622993. DOI: 10.7150/jca.86967.

B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention.

Varghese E, Samuel S, Brockmueller A, Shakibaei M, Kubatka P, Busselberg D Cancer Metastasis Rev. 2023; 43(1):115-133.

PMID: 37768439 PMC: 11016009. DOI: 10.1007/s10555-023-10137-8.

References

Zhou C, Sun B . The prognostic role of the cancer stem cell marker aldehyde dehydrogenase 1 in head and neck squamous cell carcinomas: a meta-analysis. Oral Oncol. 2014; 50(12):1144-8. DOI: 10.1016/j.oraloncology.2014.08.018. View

Penumatsa K, Edassery S, Barua A, Bradaric M, Luborsky J . Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res. 2010; 3:28. PMC: 3022900. DOI: 10.1186/1757-2215-3-28. View

Sarli L, Bottarelli L, Bader G, Iusco D, Pizzi S, Costi R . Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q. Dis Colon Rectum. 2004; 47(9):1467-82. DOI: 10.1007/s10350-004-0628-6. View

Atreya C, Sangale Z, Xu N, Matli M, Tikishvili E, Welbourn W . PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med. 2013; 2(4):496-506. PMC: 3799284. DOI: 10.1002/cam4.97. View

Wang Q, Chen Z, Du C, Wang H, Yan L, Gu J . Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology. 2009; 55(3):284-93. DOI: 10.1111/j.1365-2559.2009.03378.x. View

Reggiani Bonetti L, Migaldi M, Caredda E, Boninsegna A, Ponz de Leon M, Di Gregorio C . Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. Scand J Gastroenterol. 2012; 47(10):1211-7. DOI: 10.3109/00365521.2012.694904. View

Koren A, Rijavec M, Kern I, Sodja E, Korosec P, Cufer T . BMI1, ALDH1A1, and CD133 Transcripts Connect Epithelial-Mesenchymal Transition to Cancer Stem Cells in Lung Carcinoma. Stem Cells Int. 2016; 2016:9714315. PMC: 4685144. DOI: 10.1155/2016/9714315. View

ODwyer D, Ralton L, OShea A, Murray G . The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS One. 2011; 6(11):e27718. PMC: 3220687. DOI: 10.1371/journal.pone.0027718. View

Vander Griend D, Karthaus W, Dalrymple S, Meeker A, DeMarzo A, Isaacs J . The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res. 2008; 68(23):9703-11. PMC: 3072758. DOI: 10.1158/0008-5472.CAN-08-3084. View

10.

Vishnubalaji R, Manikandan M, Fahad M, Hamam R, Alfayez M, Kassem M . Molecular profiling of ALDH1 colorectal cancer stem cells reveals preferential activation of MAPK, FAK, and oxidative stress pro-survival signalling pathways. Oncotarget. 2018; 9(17):13551-13564. PMC: 5862598. DOI: 10.18632/oncotarget.24420. View

11.

Corbeil D, Roper K, Fargeas C, Joester A, Huttner W . Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic. 2001; 2(2):82-91. DOI: 10.1034/j.1600-0854.2001.020202.x. View

12.

Siegel R, DeSantis C, Jemal A . Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):104-17. DOI: 10.3322/caac.21220. View

13.

Horst D, Kriegl L, Engel J, Kirchner T, Jung A . CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008; 99(8):1285-9. PMC: 2570510. DOI: 10.1038/sj.bjc.6604664. View

14.

Sadek S, A Rehim D, Fatima S . The role of tumor budding in colorectal adenocarcinoma: Possible involvement of the intestinal cancer stem cell marker Lgr5. Indian J Pathol Microbiol. 2020; 63(1):32-37. DOI: 10.4103/IJPM.IJPM_154_19. View

15.

Moreno Garcia V, Batlle J, Casado E, Burgos E, De Castro J, Belda C . Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy. Colorectal Dis. 2010; 13(9):989-98. DOI: 10.1111/j.1463-1318.2010.02386.x. View

16.

Vaiopoulos A, Kostakis I, Koutsilieris M, Papavassiliou A . Colorectal cancer stem cells. Stem Cells. 2012; 30(3):363-71. DOI: 10.1002/stem.1031. View

17.

Ricci-Vitiani L, Lombardi D, Pilozzi E, Biffoni M, Todaro M, Peschle C . Identification and expansion of human colon-cancer-initiating cells. Nature. 2006; 445(7123):111-5. DOI: 10.1038/nature05384. View

18.

Nagata T, Sakakura C, Komiyama S, Miyashita A, Nishio M, Murayama Y . Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer. Anticancer Res. 2011; 31(2):495-500. View

19.

Horst D, Kriegl L, Engel J, Kirchner T, Jung A . Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 2009; 27(8):844-50. DOI: 10.1080/07357900902744502. View

20.

Vermeulen L, de Sousa E Melo F, Richel D, Medema J . The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012; 13(2):e83-9. DOI: 10.1016/S1470-2045(11)70257-1. View